Radiotherapy for Lung Metastases: Conventional to Stereotactic Body Radiation Therapy

IF 2.6 3区 医学 Q3 ONCOLOGY Seminars in Radiation Oncology Pub Date : 2023-04-01 DOI:10.1016/j.semradonc.2022.11.007
Avipsa Das , Meredith Giuliani , Andrea Bezjak
{"title":"Radiotherapy for Lung Metastases: Conventional to Stereotactic Body Radiation Therapy","authors":"Avipsa Das ,&nbsp;Meredith Giuliani ,&nbsp;Andrea Bezjak","doi":"10.1016/j.semradonc.2022.11.007","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>The lung parenchyma and adjacent tissues are one of the most common sites of </span>metastatic disease<span>. Traditionally, the approach to treatment of a patient with </span></span>lung metastases has been with systemic therapy, with </span>radiotherapy<span> being reserved for palliative management of symptomatic disease. The concept of oligo metastatic disease has paved the way for more radical treatment options, administered either alone or as local consolidative therapy in addition to systemic treatment. The modern-day management of lung metastases is guided by a number of factors, including the number of lung metastases, extra-thoracic disease status, overall performance status, and life expectancy, which all help determine the goals of care. Stereotactic body radiotherapy (SBRT) has emerged as a safe and effective method in locally controlling lung metastases, in the oligo metastatic or oligo-recurrent setting. This article outlines the role of radiotherapy in multimodality management of lung metastases.</span></p></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"33 2","pages":"Pages 172-180"},"PeriodicalIF":2.6000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053429622000790","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The lung parenchyma and adjacent tissues are one of the most common sites of metastatic disease. Traditionally, the approach to treatment of a patient with lung metastases has been with systemic therapy, with radiotherapy being reserved for palliative management of symptomatic disease. The concept of oligo metastatic disease has paved the way for more radical treatment options, administered either alone or as local consolidative therapy in addition to systemic treatment. The modern-day management of lung metastases is guided by a number of factors, including the number of lung metastases, extra-thoracic disease status, overall performance status, and life expectancy, which all help determine the goals of care. Stereotactic body radiotherapy (SBRT) has emerged as a safe and effective method in locally controlling lung metastases, in the oligo metastatic or oligo-recurrent setting. This article outlines the role of radiotherapy in multimodality management of lung metastases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肺转移瘤的放射治疗:常规到立体定向身体放射治疗
肺实质和邻近组织是转移性疾病最常见的部位之一。传统上,肺转移患者的治疗方法是全身治疗,放疗保留用于症状性疾病的姑息治疗。寡转移性疾病的概念为更激进的治疗选择铺平了道路,可以单独使用,也可以作为全身治疗之外的局部巩固治疗。肺转移的现代管理由许多因素指导,包括肺转移的数量、胸外疾病状态、整体表现状态和预期寿命,这些都有助于确定护理目标。立体定向放射治疗(SBRT)已成为一种安全有效的局部控制肺转移的方法,无论是在少转移还是少复发的情况下。本文概述了放射治疗在肺转移瘤多模式治疗中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.80
自引率
0.00%
发文量
48
审稿时长
>12 weeks
期刊介绍: Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.
期刊最新文献
Radiation as an Immune Modulator: Where We Are With Modern Total Body Irradiation. Radiation for Multiple Myeloma in the Era of Novel Agents: Indications, Safety, and Dose Selection. Rising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape of Treatment for Classic Hodgkin Lymphoma. Translating Between Radiation Dose and Late Toxicity for Lymphoma Survivors: Implications on Toxicity Counseling and Survivorship. Advanced Stage Hodgkin and Diffuse Large B-Cell Lymphomas: Is There Still a Role for Consolidation Radiotherapy in the PET Era?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1